Protagonist Therapeutics Inc (PTGX) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) came in at $-0.62, exceeding Wall Street's consensus estimate of $-0.65 by $0.03. Revenue remained at $0.0B, in line with expectations.
This update provides insight into Protagonist's operational performance and financial health. The firm, headquartered in Newark, California, focuses on discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its clinical programs target diseases in hematology, blood disorders, and inflammatory conditions.
Protagonist’s lead candidates, rusfertide and icotrokinra, are currently in advanced Phase III clinical development. Rusfertide (PTG-300) is an injectable hepcidin mimetic aimed at treating polycythemia vera and other blood disorders. Icotrokinra is an oral IL-23R specific antagonist for conditions such as psoriasis and inflammatory bowel disease.
The company will host an earnings conference call after market close to discuss these results and provide further insights into business performance. Investors are encouraged to review the full earnings release and management commentary for complete context on the quarter's performance and future outlook.
Protagonist Therapeutics has a market cap of $4,854.35 and a trailing P/E ratio of 93.28. Upcoming earnings are scheduled for May 3, 2026, with an EPS estimate of $-0.2818 and revenue expected to remain at $0.0B.